Pharmaceutical use of LncRNA DCRT and medicine, screening method and preparation method thereof for treating cardiovascular diseases
By targeting the upregulation of lncRNA DCRT, the problem of mitochondrial function abnormalities in central myocytes of dilated cardiomyopathy was solved, and the cardiac function impaired and cardiomyocardial contractility was significantly improved, providing an effective treatment of dilated cardiomyopathy.
Patent Information
- Application Number
- CN202310099726.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-06
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-02-06
AI Technical Summary
The existing treatment of dilated cardiomyopathy still has insufficient effectiveness and lacks effective targets for mitochondrial abnormalities in cardiomyocytes, resulting in limited therapeutic effects.
An anti-diffusion cardiomyopathy drug with lncRNA DCRT as a drug target was developed. By upregulating the expression of lncRNA DCRT, it regulates its function in cardiomyocytes, improves impaired cardiac function and pathological increase in cardiomyocyte area.
Through animal experiment verification, it was found that upregulating lncRNA DCRT significantly improved the impairment of cardiac function and cardiomyocyte contractility dysfunction induced by thoracic aorta, providing an effective treatment plan for dilated cardiomyopathy.
Smart Images

Figure CN116270708B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the pharmaceutical field of cardiovascular diseases, and specifically relates to pharmaceutical uses of LncRNA DCRT and drugs, screening methods and preparation methods thereof for treating cardiovascular diseases. Background Art
[0002] Heart failure is a complex syndrome caused by various cardiac structural or functional diseases that result in impaired ventricular filling and / or ejection capacity, significantly increasing the risk of hospitalization and death worldwide. Despite advances in scientific research and treatment methods, the treatment of heart failure remains a difficult problem. Dilated cardiomyopathy is one of the most common causes of heart failure, which is defined as left ventricular systolic dysfunction and dilation in the absence of coronary artery disease or under abnormal load conditions proportional to the degree of left ventricular damage. Dilated cardiomyopathy is a clinical syndrome of different cardiovascular diseases at the end stage of development. It has a poor prognosis and high mortality rate. It is one of the main causes that threaten human health and increase medical burden. Despite recent advances in treatment, a large number of patients with dilated cardiomyopathy still suffer from arrhythmias, heart failure and sudden cardiac death. Dilated cardiomyopathy ranks third among various cardiovascular diseases that lead to heart failure and is the leading cause of heart transplantation.
[0003] For the pathogenesis of dilated cardiomyopathy, genetic mutations in genes involved account for 35% of cases. Endocrine abnormalities, drugs and poisons, and infectious factors are all causes of acquired dilated cardiomyopathy. Importantly, mitochondrial dysfunction plays a vital role in the pathogenesis of dilated cardiomyopathy. Mitochondria are the "powerhouse" of eukaryotic cells and are highly dynamic organelles that are particularly important for cells that require high energy, such as cardiomyocytes. Mitochondria provide a large amount of adenosine triphosphate every day to maintain cardiac function through oxidative phosphorylation. Mutations in genes encoding mitochondrial proteins often lead to abnormal oxidative phosphorylation, which not only leads to ATP deficiency, but also leads to increased ROS production, as well as changes in the antioxidant defense system, which may ultimately promote the development of dilated cardiomyopathy. Therefore, maintaining normal mitochondrial function in cardiomyocytes can serve as a new target for the treatment of heart failure.
[0004] Long non-coding RNA is a newly discovered class of non-coding RNA with a nucleotide sequence greater than 200 nt and important regulatory gene expression. Recently, more and more studies have found that lncRNA plays an important role in a variety of cardiovascular diseases, including myocardial metabolism, myocardial hypertrophy, cardiac conduction system and heart development. Elucidating the molecular mechanism of lncRNA function is a major challenge in this field. In recent years, more and more studies have shown that lncRNA is involved in various processes of gene expression in the disease process, including transcriptional regulation, post-transcriptional regulation and epigenetic regulation. LncRNA function can regulate the expression level of downstream target genes through cis or trans. The mechanism of action of lncRNA localized in different subcellular structures is different. The cytoplasmic and nuclear localization of lncRNA helps us determine the mode of action of lncRNA. lncRNA localized in the nucleus may affect gene transcription through various mechanisms, including epigenetic modification, interaction with transcription factors, and affecting mRNA processing or output. The main modes of action of lncRNA distributed in the cytoplasm include: affecting the stability of mRNA, affecting translation initiation, competing with endogenous RNA, or affecting post-translational modification, etc. Due to the lack of conservation between species, although many studies have reported the function and mechanism of action of long non-coding RNA in mouse models, little is known about their role in the human heart.
[0005] So far, there are no reports on the association between lncRNA DCRT and cardiovascular disease. Summary of the invention
[0006] Based on the objective problems and deficiencies in this field, the inventors accidentally discovered the relationship between lncRNA DCRT and the pathogenesis of dilated cardiomyopathy, and further conducted molecular experiments to develop an anti-dilated cardiomyopathy drug with lncRNA DCRT as a drug target. At the same time, animal experiments were conducted to verify its effect. It was found that molecules with lncRNA DCRT as a drug target and upregulating the expression of DCRT can significantly improve the impaired cardiac function and pathological increase in myocardial cell area in dilated cardiomyopathy.
[0007] The technical solution of the present invention is as follows:
[0008] Pharmaceutical use of lncRNA DCRT whose sequence is shown in SEQ ID NO.1.
[0009] The reverse complementary sequence of the lncRNA DCRT is shown in SEQ ID NO.2;
[0010] Preferably, the drug is a drug for treating cardiovascular diseases.
[0011] The cardiovascular disease is dilated cardiomyopathy.
[0012] A drug for treating cardiovascular diseases, characterized in that the pharmacologically active ingredient thereof uses the lncRNA DCRT with a sequence as shown in SEQ ID NO.1 as a drug target.
[0013] The pharmaceutically active ingredients include: substances that regulate the expression of lncRNA DCRT.
[0014] The regulation refers to positive regulation;
[0015] Preferably, the substance regulating the expression of lncRNA DCRT is selected from the group consisting of: a primer for up-regulating expression or over-expressing lncRNA DCRT, a recombinant expression vector for up-regulating expression or over-expressing lncRNA DCRT, and a transformant for up-regulating expression or over-expressing lncRNA DCRT;
[0016] Preferably, the primers for up-regulating or over-expressing lncRNA DCRT include: positive primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′,
[0017] Anti-primer: 5′-AAAATGTTCCGCCCCTCC-3′;
[0018] Preferably, the recombinant expression vector for up-regulating expression or over-expressing lncRNA DCRT refers to an expression vector connected to the amplification product of the primer for up-regulating expression or over-expressing lncRNA DCRT;
[0019] Preferably, the expression vector is selected from: pAAV vector;
[0020] Preferably, the transformant that up-regulates or over-expresses lncRNA DCRT is a host transformed with the above-mentioned recombinant expression vector;
[0021] Preferably, the host is selected from a recombinant adeno-associated virus or a cell;
[0022] Preferably, the drug further comprises: pharmaceutical excipients;
[0023] Preferably, the cardiovascular disease is dilated cardiomyopathy.
[0024] A method for preparing a drug for treating cardiovascular diseases, characterized in that a substance that upregulates expression or overexpresses lncRNA DCRT is used as the pharmacologically active ingredient of the drug; the sequence of lncRNA DCRT is such as SEQ ID NO.1.
[0025] The drug is prepared by mixing a substance that upregulates or overexpresses lncRNA DCRT with a pharmaceutical excipient;
[0026] Preferably, the substance that upregulates expression or overexpresses lncRNA DCRT is selected from the group consisting of: a primer that upregulates expression or overexpresses lncRNA DCRT, a recombinant expression vector that upregulates expression or overexpresses lncRNA DCRT, and a transformant that upregulates expression or overexpresses lncRNA DCRT;
[0027] Preferably, the primers for up-regulating or over-expressing lncRNA DCRT include: positive primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′,
[0028] Anti-primer: 5′-AAAATGTTCCGCCCCTCC-3′;
[0029] Preferably, the recombinant expression vector for up-regulating expression or over-expressing lncRNA DCRT refers to an expression vector connected to the amplification product of the primer for up-regulating expression or over-expressing lncRNA DCRT;
[0030] Preferably, the expression vector is selected from: pAAV vector;
[0031] Preferably, the transformant that up-regulates or over-expresses lncRNA DCRT is a host transformed with the above-mentioned recombinant expression vector;
[0032] Preferably, the host is selected from a recombinant adeno-associated virus or a cell;
[0033] Preferably, the cardiovascular disease is dilated cardiomyopathy.
[0034] A method for screening drugs for treating cardiovascular diseases, comprising: screening candidate substances with lncRNA DCRT as a target; the sequence of lncRNA DCRT is such as SEQ ID NO.1.
[0035] The method for screening a drug for treating cardiovascular diseases further comprises: further screening a substance that regulates the expression of lncRNA DCRT from the candidate substances as a pharmacologically active ingredient of the drug;
[0036] Preferably, the regulation refers to positive regulation;
[0037] Preferably, the substance that regulates the expression of lncRNA DCRT is selected from: a substance that upregulates the expression or overexpresses lncRNA DCRT;
[0038] Preferably, the substance that upregulates expression or overexpresses lncRNA DCRT is selected from the group consisting of: a primer that upregulates expression or overexpresses lncRNA DCRT, a recombinant expression vector that upregulates expression or overexpresses lncRNA DCRT, and a transformant that upregulates expression or overexpresses lncRNA DCRT;
[0039] Preferably, the primers for up-regulating or over-expressing lncRNA DCRT include: positive primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′,
[0040] Anti-primer: 5′-AAAATGTTCCGCCCCTCC-3′;
[0041] Preferably, the recombinant expression vector for up-regulating expression or over-expressing lncRNA DCRT refers to an expression vector connected to the amplification product of the primer for up-regulating expression or over-expressing lncRNA DCRT;
[0042] Preferably, the expression vector is selected from: pAAV vector;
[0043] Preferably, the transformant that up-regulates or over-expresses lncRNA DCRT is a host transformed with the above-mentioned recombinant expression vector;
[0044] Preferably, the host is selected from a recombinant adeno-associated virus or a cell;
[0045] Preferably, the cardiovascular disease is dilated cardiomyopathy.
[0046] The present invention provides a drug for treating dilated cardiomyopathy. The active ingredient of the drug takes lncRNA DCRT as a drug target, and the drug effect of treating dilated cardiomyopathy is achieved by upregulating the expression of the lncRNA DCRT.
[0047] The present invention is further configured as follows: the medicinal ingredient includes a substance that upregulates expression or overexpresses lncRNA DCRT, and the sequence of the lncRNA DCRT is shown in SEQ ID NO.1.
[0048] By adopting the above technical solution, the active ingredients of the drug include substances that upregulate or overexpress lncRNA DCRT, thereby increasing the expression level of lncRNA DCRT and further treating the disease.
[0049] The present invention is further configured to include pharmaceutically acceptable excipients.
[0050] By adopting the above technical solution, those skilled in the art can add various pharmaceutically acceptable adjuvants / excipients to the anti-dilated cardiomyopathy drug of the present invention according to objective needs to prepare various dosage forms for easy sales or promotion.
[0051] The present invention is further configured to include a reagent for buffering, and / or synthesizing, and / or purifying the lncRNA DCRT.
[0052] The present invention also provides a drug for treating dilated cardiomyopathy, wherein the active ingredients of the drug have a degradation or inhibition effect on substances that down-regulate the sequence expressing lncRNA DCRT.
[0053] The present invention also provides a method for screening anti-dilated cardiomyopathy drugs, which detects whether the selected substance can up-regulate the expression of lncRNA DCRT.
[0054] The present invention also provides use of a substance capable of up-regulating the expression of lncRNA DCRT in preparing an anti-dilated cardiomyopathy drug.
[0055] The present invention also provides a use of a full-length sequence fragment of lncRNA DCRT in preparing a drug for treating dilated cardiomyopathy. The full-length sequence fragment of lncRNA DCRT is shown in SEQ ID NO.1.
[0056] Another aspect of the present invention provides the use of a substance that can upregulate the expression of the lncRNA DCRT in the preparation of an anti-dilated cardiomyopathy drug. Any scale of putting the above substances into a product package marked with anti-dilated cardiomyopathy use for commercial purposes falls within the scope of protection claimed by the present invention.
[0057] The beneficial effects of the present invention are:
[0058] The present invention originally discovered the highly conserved lncRNA DCRT in the heart tissue of patients with dilated cardiomyopathy. The lncRNA DCRT is mainly located in the nucleus of cardiomyocytes and is significantly reduced in the cardiomyocytes of patients with dilated cardiomyopathy. Subsequently, animal experiments confirmed that upregulating lncRNA DCRT has the effect of improving the impaired central function and pathological increase in cardiomyocyte area in the heart dilation model induced by thoracic aortic constriction.
[0059] In order to achieve the purpose of treating dilated cardiomyopathy, the present invention uses lncRNA DCRT in animal experiments, and it is confirmed in animal experiments that the synthesis of lncRNA DCRT can significantly improve the impaired cardiac function and myocardial cell contractility disorder induced by thoracic aortic stenosis, thereby achieving the purpose of auxiliary treatment of dilated cardiomyopathy. Therefore, based on the above findings and results, the present invention provides a drug for the clinical treatment of dilated cardiomyopathy with lncRNA DCRT as a therapeutic target.
[0060] Based on the base sequence of lncRNA DCRT, the present invention designs and synthesizes the sequence expressing lncRNA DCRT. The lncRNA DCRT synthetic product can significantly improve the impaired cardiac function, myocardial cell contractility disorder and calcium ion instability induced by thoracic aortic stenosis. Thus, it is shown that lncRNA DCRT has the potential to improve dilated cardiomyopathy.
[0061] The present invention found through experiments that the expression of lncRNA DCRT in the heart tissue of patients with dilated cardiomyopathy was reduced ( Figure 1 A), and lncRNA DCRT is significantly reduced mainly in the cardiomyocytes of patients with dilated cardiomyopathy. In vivo experiments have found that increasing the full-length synthesis of lncRNA DCRT can significantly improve the impaired cardiac function and pathological increase in cardiomyocyte area induced by thoracic aortic constriction, achieving the purpose of auxiliary treatment of dilated cardiomyopathy. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 A is the total expression level of lncRNADCRT in the heart tissue of patients with dilated cardiomyopathy and the control group in Experimental Example 1 of the present invention, and it was found that the content of lncRNA DCRT decreased in patient samples; wherein the ordinate "Relative DCRTLevel" refers to the relative expression level of lncRNA DCRT, the abscissa Normal refers to the control group, and DCM refers to patients with dilated cardiomyopathy.
[0063] Figure 1 B The three rows of photos from top to bottom are the expression of lncRNA DCRT in cardiac cells, fibroblasts and endothelial cells in the human heart tissue in Experimental Example 1 of the present invention. Among them, cTNT is a specific marker for myocardial cells, which refers to myocardial cell staining; Col1a1 is a specific marker for fibroblasts, which refers to fibroblast staining; CD31 is a specific marker for endothelial cells, which refers to endothelial cell staining; DAPI refers to the result of DAPI staining of cell nuclei; Merge refers to the merged picture of the previous three pictures in the same row.
[0064] The expression detection method of cTNT, Col1a1, and CD31 and the DAPI staining operation can refer to the methods and steps described in the article "LncRNA ZNF593-ASAlleviates Contractile Dysfunction in Dilated Cardiomyopathy".
[0065] Figure 2 The present invention is experimental example 2 to detect the therapeutic effect of lncRNA DCRT on dilated cardiomyopathy; wherein, Figure 2 The ordinate of the left figure of A refers to the ejection fraction, the ordinate of the right figure refers to the shortening fraction, the GFP on the abscissa of the left and right figures refers to the negative control mice that only overexpress green fluorescent protein, and mDCRT refers to the mice that overexpress lncRNA DCRT; Sham refers to the sham-operated group mice, and TAC refers to the aortic arch constriction (TAC) disease model mice;
[0066] The operation of overexpressing GFP, the method of constructing Sham mice, and the method of constructing aortic arch constriction (TAC) disease model mice can refer to the methods and steps described in the article "LncRNA ZNF593-AS Alleviates Contractile Dysfunction in Dilated Cardiomyopathy".
[0067] Figure 2 The vertical axis of the left graph of B refers to the maximum rate of increase of left ventricular pressure (dp / dt max ), the vertical axis of the right figure refers to the maximum rate of change of left ventricular diastolic pressure drop (dp / dt min ), the GFP in the horizontal axis of the left and right figures refers to the negative control mice that only overexpressed green fluorescent protein, and mDCRT refers to the mice that overexpressed lncRNA DCRT; Sham refers to the sham-operated group mice, and TAC refers to the aortic arch constriction (TAC) disease model mice;
[0068] Figure 2 C is a graph showing the detection results of the area of myocardial cells in mice after high expression of lncRNA DCRT in the mouse heart in Experimental Example 2 of the present invention; wherein, the left graph is a graph showing the results of WGA staining, and the right graph is a bar graph showing the area of myocardial cells; mDCRT in the left graph refers to mice overexpressing lncRNA DCRT; Sham refers to mice in the sham operation group, and TAC refers to mice in the aortic arch constriction (TAC) disease model; the ordinate in the right graph refers to the area of myocardial cells, and the GFP in the abscissa refers to negative control mice overexpressing only green fluorescent protein, and mDCRT refers to mice overexpressing lncRNA DCRT. DETAILED DESCRIPTION
[0069] The technical solution of the present invention will be clearly and completely described below in conjunction with specific embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0070] Instruments and Equipment
[0071] ND-1000 Nucleic Acid Analyzer
[0072] ABI 9700PCR Instrument
[0073] ABI 7900HT Fluorescence Real-time Quantitative PCR Instrument
[0074] Beckman X-15R Low Temperature High Speed Centrifuge
[0075] Reagents and consumables
[0076] TRIZOL was purchased from Invitrogen;
[0077] The reverse transcription kit was purchased from Thermofisher;
[0078] SYBR Green was purchased from Thermofisher;
[0079] EasyPure Plasmid MiniPrep Kit was purchased from Beijing Quanshijin Company.
[0080] Sources of biological materials
[0081] Peripheral blood of patients with dilated cardiomyopathy was obtained from inpatients at Wuhan Tongji Hospital from 2012 to 2018, and all of them signed informed consent;
[0082] C57BL / 6 was obtained from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.
[0083] Group 1 Example: Pharmaceutical Use of lncRNA DCRT of the Present Invention
[0084] This group of embodiments provides pharmaceutical uses of lncRNA DCRT whose sequence is shown in SEQ ID NO.1.
[0085] In some embodiments, the reverse complementary sequence of the lncRNA DCRT is as SEQ ID NO.2.
[0086] In a specific embodiment, the drug is a drug for treating cardiovascular disease.
[0087] In a more specific embodiment, said cardiovascular disease is dilated cardiomyopathy.
[0088] The present invention discloses for the first time the pharmaceutical use of lncRNA DCRT shown in SEQ ID NO.1. Those skilled in the art can obtain guidance and inspiration based on the content disclosed in the present invention and use lncRNA DCRT shown in SEQ ID NO.1 for pharmaceutical use. Any act of synthesizing, amplifying, preparing, producing, using, expressing, secreting, enriching, propagating, selling, offering for sale, importing, and exporting lncRNA DCRT shown in SEQ ID NO.1 for any medicinal or commercial purpose falls within the protection scope of the present invention.
[0089] The drug is not limited to the treatment of cardiovascular diseases. Those skilled in the art can obtain guidance and inspiration based on the content disclosed in the present invention, and use the lncRNA DCRT shown in SEQ ID NO.1 to treat other diseases besides cardiovascular diseases. Any use of the lncRNA DCRT shown in SEQ ID NO.1 as a drug target for the treatment of any disease falls within the scope of protection of the present invention.
[0090] Group 2 Examples: Drugs for treating cardiovascular diseases according to the present invention
[0091] This group of embodiments provides a drug for treating cardiovascular diseases. All embodiments in this group have the following common features: the pharmacologically active ingredient of the drug uses the lncRNA DCRT shown in SEQ ID NO.1 as a drug target.
[0092] In a specific embodiment, the drug for treating cardiovascular disease comprises: a pharmacologically active ingredient, characterized in that the pharmacologically active ingredient comprises: a substance that regulates the expression of lncRNA DCRT.
[0093] In some embodiments, the regulation refers to positive regulation;
[0094] Preferably, the substance regulating the expression of lncRNA DCRT is selected from the group consisting of: a primer for up-regulating expression or over-expressing lncRNA DCRT, a recombinant expression vector for up-regulating expression or over-expressing lncRNA DCRT, and a transformant for up-regulating expression or over-expressing lncRNA DCRT;
[0095] Preferably, the primers for upregulating expression or overexpressing lncRNA DCRT include:
[0096] Positive primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′,
[0097] Anti-primer: 5′-AAAATGTTCCGCCCCTCC-3′;
[0098] Preferably, the recombinant expression vector for up-regulating or over-expressing lncRNA DCRT refers to an expression vector connected to the amplification product of the above primers;
[0099] In a specific embodiment, the expression vector is selected from: a pAAV vector;
[0100] Preferably, the transformant that up-regulates or over-expresses lncRNA DCRT is a host transformed with the above-mentioned recombinant expression vector;
[0101] In a specific embodiment, the host is selected from a recombinant adeno-associated virus or a cell;
[0102] Preferably, the drug further comprises: pharmaceutical excipients;
[0103] Preferably, the cardiovascular disease is dilated cardiomyopathy.
[0104] This group of more specific embodiments provides a drug for treating dilated cardiomyopathy. In this group of embodiments, all of them have the following characteristics: the active ingredient of the drug for treating dilated cardiomyopathy uses lncRNA DCRT as a drug target, and the drug effect of treating dilated cardiomyopathy is achieved by upregulating the expression of the lncRNA DCRT. The present invention found through experiments that the sequence of lncRNA DCRT is highly conserved, the content of lncRNA DCRT in patients with dilated cardiomyopathy is significantly lower than that in the control group, and the lncRNA DCRT in the main myocardial cells is significantly decreased. Afterwards, animal experiments confirmed that upregulating lncRNA DCRT has the effect of improving the impaired central function and reduced contractility of myocardial cells in the heart dilation model induced by thoracic aortic coarctation, thereby achieving the purpose of auxiliary treatment of dilated cardiomyopathy.
[0105] In a further embodiment, the pharmacological ingredients of the drug include substances that upregulate the expression of the lncRNA DCRT; or the pharmacological ingredients of the drug have a degrading or inhibitory effect on the substance that downregulates the expression of the lncRNA DCRT. lncRNA DCRT, as a segment of RNA obtained exogenously in an animal, can be expressed by molecular biological means to upregulate its level and thus play a therapeutic role. Other means, such as certain chemical molecules, can also be used to inhibit its degradation, which can also achieve the purpose of upregulating its level.
[0106] In a preferred embodiment, the active ingredient of the drug contains the full-length sequence fragment of lncRNA DCRT, thereby increasing its expression level and further treating the disease.
[0107] In other embodiments, the drug further includes pharmaceutically acceptable excipients, and / or reagents for buffering, synthesizing, and / or purifying the lncRNA DCRT sequence fragment. Those skilled in the art can add various pharmaceutically acceptable adjuvants / excipients to the anti-dilated cardiomyopathy drug of the present invention according to objective needs to prepare various dosage forms for easy sales or promotion.
[0108] In a specific embodiment, the pharmaceutically acceptable excipients or pharmaceutical excipients are selected from: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, and release retardants.
[0109] Those skilled in the art can make routine selections or adjustments to pharmaceutical excipients based on actual production needs, combined with conventional technical means or basic common sense of pharmaceutical production processes (e.g., "Encyclopedia of Pharmaceutical Technology", "Pharmaceutical Preparation Technology", etc.), and then prepare drugs with different dosage forms, different storage conditions, and different shelf lives. This is possible and easy to do without technical barriers for those skilled in the art.
[0110] Those skilled in the art can select and prepare the above-mentioned excipients, and prepare the lncRNA DCRT and / or the substance regulating the expression of lncRNA DCRT of the present invention into different dosage forms, such as powder, tablet, oral liquid, capsule, granule, spray, gel, paste, decoction, pill, spray, inhalant, atomizer, injection, etc.
[0111] The third group of embodiments, the preparation method of the drug of the present invention
[0112] This group of embodiments provides a method for preparing a drug for treating cardiovascular diseases, characterized in that a substance that upregulates expression or overexpresses lncRNA DCRT is used as the pharmacologically active ingredient of the drug; the sequence of lncRNA DCRT is such as SEQID NO.1.
[0113] In a specific embodiment, the drug is prepared by mixing a substance that upregulates or overexpresses lncRNA DCRT with a pharmaceutical excipient;
[0114] Preferably, the substance that upregulates expression or overexpresses lncRNA DCRT is selected from the group consisting of a primer that upregulates expression or overexpresses lncRNA DCRT, a recombinant expression vector that upregulates expression or overexpresses lncRNA DCRT, and a transformant that upregulates expression or overexpresses lncRNA DCRT;
[0115] In a preferred embodiment, the primers for upregulating expression or overexpressing lncRNA DCRT include:
[0116] Positive primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′,
[0117] Anti-primer: 5′-AAAATGTTCCGCCCCTCC-3′;
[0118] Preferably, the recombinant expression vector for up-regulating or over-expressing lncRNA DCRT refers to an expression vector connected to the amplification product of the above primers;
[0119] In a specific embodiment, the expression vector is selected from: a pAAV vector;
[0120] Preferably, the transformant that up-regulates or over-expresses lncRNA DCRT is a host transformed with the above-mentioned recombinant expression vector;
[0121] In a specific embodiment, the host is selected from a recombinant adeno-associated virus or a cell;
[0122] Preferably, the cardiovascular disease is dilated cardiomyopathy.
[0123] The present invention provides the use of a substance that can upregulate the expression of the lncRNA DCRT in the preparation of an anti-dilated cardiomyopathy drug. Any behavior of packing the above substances into a product package marked with anti-dilated cardiomyopathy use for commercial purposes on any scale falls within the scope of protection claimed by the present invention.
[0124] The present invention provides a method for preparing an anti-dilated cardiomyopathy drug, comprising: using a substance capable of up-regulating the expression of the lncRNA DCRT as an active ingredient of the anti-dilated cardiomyopathy drug.
[0125] The specific experimental operation steps of this group of embodiments are shown in the following Experimental Example 2.
[0126] Group 4 Example, screening method for the drug of the present invention
[0127] This group of embodiments provides a method for screening drugs for treating cardiovascular diseases. All embodiments in this group have the following common features: the screening method comprises: screening candidate substances with lncRNA DCRT as a target; the sequence of lncRNA DCRT is such as SEQ ID NO.1.
[0128] In a further embodiment, the method for screening a drug for treating cardiovascular disease further comprises: further screening a substance that regulates the expression of lncRNA DCRT from the candidate substances as a pharmacologically active ingredient of the drug;
[0129] Preferably, the regulation refers to positive regulation;
[0130] Preferably, the substance that regulates the expression of lncRNA DCRT is selected from: a substance that upregulates the expression or overexpresses lncRNA DCRT;
[0131] Preferably, the substance that upregulates expression or overexpresses lncRNA DCRT is selected from the group consisting of: a primer that upregulates expression or overexpresses lncRNA DCRT, a recombinant expression vector that upregulates expression or overexpresses lncRNA DCRT, and a transformant that upregulates expression or overexpresses lncRNA DCRT;
[0132] In a preferred embodiment, the primers for upregulating expression or overexpressing lncRNA DCRT include:
[0133] Positive primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′,
[0134] Anti-primer: 5′-AAAATGTTCCGCCCCTCC-3′;
[0135] Preferably, the recombinant expression vector for up-regulating or over-expressing lncRNA DCRT refers to an expression vector connected to the amplification product of the above primers;
[0136] In a specific embodiment, the expression vector is selected from: a pAAV vector;
[0137] Preferably, the transformant that up-regulates or over-expresses lncRNA DCRT is a host transformed with the above-mentioned recombinant expression vector;
[0138] In a specific embodiment, the host is selected from a recombinant adeno-associated virus or a cell.
[0139] Preferably, the cardiovascular disease is dilated cardiomyopathy.
[0140] The most specific embodiment of this group provides a method for screening anti-dilated cardiomyopathy drugs, detecting whether the candidate substance can upregulate the expression of lncRNA DCRT, and screening out substances that can promote the expression of lncRNA DCRT.
[0141] The specific experimental operation steps of this group of embodiments can be found in Experimental Example 2.
[0142] Experimental Example 1: Detection of lncRNA DCRT in myocardial tissue of patients with dilated cardiomyopathy
[0143] Heart tissues from 14 patients with dilated cardiomyopathy and 7 healthy heart transplant donors were collected and stored in a -80°C refrigerator. 1 ml of TRIZOL (Invitrogen) was added to each 50 mg of heart, ground, and RNA was extracted. ND-1000 was used to detect RNA quality.
[0144] The results showed that the expression of lncRNA DCRT in cardiac tissue of patients with dilated cardiomyopathy was decreased ( Figure 1 A); In cardiac tissue, lncRNA DCRT is mainly located in the nucleus of cardiomyocytes ( Figure 1 B).
[0145] Experimental Example 2: Detection of the therapeutic effect of lncRNA DCRT on dilated cardiomyopathy
[0146] 1. Packaging and purification of transformants overexpressing lncRNA DCRT
[0147] This experiment requires packaging two viruses: rAAV-GFP (negative control) carrying green fluorescent protein (GFP) and rAAV-DCRT (upregulating DCRT) carrying lncRNA DCRT; the reverse complementary sequence of lncRNA DCRT is shown in SEQ ID NO.2. Hind III and Not I sticky ends were added to the oligonucleotide single strand and then submitted to Shanghai Shenggong Biotechnology Technology Service Co., Ltd. for synthesis. Annealing to form a double strand, the system is as follows:
[0148]
[0149]
[0150] After the system was mixed and centrifuged, annealing reaction was performed on a PCR instrument with the following program: 95°C for 2 minutes, decreasing by 1°C every 90 seconds until it reached 25°C, and then set aside at 4°C.
[0151] A. pAAV vector digestion
[0152]
[0153] The system was mixed and centrifuged, and then reacted at 37°C for 2 hours.
[0154] B. Rubber tapping, recovery and purification
[0155] Add the digested product to 1% agarose gel for electrophoresis, cut out the gel block containing the target fragment under UV light, and purify the nucleic acid fragment using a gel recovery kit. The steps are as follows:
[0156] a) Weigh the gel block, add an appropriate volume of GSB solution according to the weight of the gel block, and place in a 55°C water bath for 10 minutes, inverting the solution three times during the mixing process until the gel is completely dissolved;
[0157] b) After the liquid is cooled to room temperature, it is added to the centrifuge column, allowed to stand for 1 minute, centrifuged at 10,000 g for 1 minute, and the liquid in the collection tube is discarded;
[0158] c) 650ul WB solution, centrifuge at 10000g for 1 minute, and discard the liquid in the collection tube;
[0159] d) Centrifuge at 10,000 g for 2 minutes, place the spin column in a new EP tube, and leave it uncapped for 10 minutes;
[0160] e) Add 50ul of EB preheated at 65℃ to the center of the centrifuge column, let it stand for 1 minute, and centrifuge at 10000g for 1 minute. The eluent is the purified nucleic acid solution.
[0161] C. Connect the target fragment to the vector
[0162]
[0163]
[0164] The system (10 ul) was mixed and centrifuged, and then connected at 16°C overnight.
[0165] D. Competent transformation
[0166] Take the T1 competent bacteria out of the -80℃ refrigerator, thaw on ice for 30 minutes, add the above-mentioned ligation product to the competent state, stand on ice for 30 minutes, heat shock in a 42℃ water bath for 45s, ice bath for 5 minutes, add 200ul LB medium without antibiotics (tryptone 10g / L, yeast extract 5g / L, NaCl10g / L, pH 7.4), and shake at 100 rpm for 1 hour on a 37℃ shaker. Apply the bacterial solution on a solid LB (tryptone 10g / L, yeast extract 5g / L, NaCl 10g / L, agar powder 15g / L) culture plate containing 100ug / ml ampicillin, and culture in a 37℃ incubator overnight. Select the grown monoclonal colonies to amplify in liquid LB medium containing ampicillin, send the bacterial solution to Wuhan Tianyi Huiyuan Biotechnology Co., Ltd. for sequencing, and amplify and preserve the strains with correct sequencing.
[0167] Plasmid extraction
[0168] The constructed pAAV-DCRT, pAAV-GFP, pXX9 and phelper bacterial solutions were amplified in TB medium (tryptone 12 g / L, yeast extract 24 g / L, K2HPO4·3H2O 16.43 g / L, KH2PO4 2.31 g / L, 0.4% glycerol) containing 100 ug / ml ampicillin for 14-16 hours, and the plasmids were extracted using the endotoxin-free plasmid extraction kit of Tiangen Biochemical Technology Co., Ltd. The specific steps are as follows:
[0169] a) Centrifuge the bacterial solution at 8000g for 3 minutes at room temperature to collect the bacteria, remove the supernatant, add new bacterial solution, collect the bacteria at the bottom of the centrifuge tube by repeated centrifugation, and remove the supernatant by aspiration;
[0170] b) Add an appropriate amount of P1 solution (add RNase A first) and use a pipette and oscillator to completely resuspend the bacterial pellet;
[0171] c) Add an appropriate amount of P2 solution, immediately invert it 7 times, and let it stand at room temperature for 5 minutes;
[0172] d) Add an appropriate amount of P4 solution, immediately invert several times until flocculent precipitation appears in the solution, let it stand at room temperature for 10 minutes, centrifuge at 8228g for 15 minutes at room temperature, and filter the supernatant with filter CS1 into a clean centrifuge tube;
[0173] e) Add isopropanol at a volume ratio of 1:0.3, mix well and transfer 10 ml to adsorption column CP6 (previously treated with equilibration solution BL), centrifuge at 8228 g for 2 minutes at room temperature, discard the waste liquid in the collection tube, and repeat the column with the remaining solution;
[0174] f) Add 10 ml of PW rinse solution (add ethanol first), centrifuge at 8228 g for 2 minutes at room temperature, and discard the waste liquid in the collection tube;
[0175] g) repeat step f;
[0176] h) Add 3 ml of anhydrous ethanol, centrifuge at 8228 g for 2 minutes at room temperature, and discard the waste liquid in the collection tube;
[0177] i) Centrifuge at 8228 g for 5 minutes at room temperature, place the adsorption column in a clean collection tube, and leave it uncapped for 15 minutes;
[0178] j) Add 1 ml of elution buffer TB to the adsorption column, let it stand at room temperature for 5 minutes, centrifuge at 8228g for 2 minutes at room temperature, elute the adsorption column again with 0.5 ml TB, transfer the eluate to an EP tube, and use NanoDrop2000 to detect the concentration and purity of the plasmid.
[0179] E. Virus Packaging
[0180] This experiment uses the three-plasmid calcium-phosphate co-transfection method to package viruses in HEK 293T cells. HEK 293T cells are subcultured into a cell culture dish with a diameter of 15 cm. When the cells grow to about 85%, replace the complete culture medium and add each reagent in the following order to prepare the plasmid transfection solution (for each culture dish):
[0181]
[0182] *HEBS solution (NaCl 280mM, HEPES 50mM, Na2HPO4 1.5mM, KCl 10mM, D-glucose 12mM, pH 6.80-7.05)
[0183] The above-mentioned plasmid transfection solution was dripped into the HEK 293T cell dish, and after culturing for 12 hours, the high-glucose DMEM medium containing 5% fetal bovine serum was replaced, and the culture was continued for 48-60 hours, and the cells were collected and stored in a -80°C refrigerator.
[0184] F. Virus Purification
[0185] The cells were repeatedly frozen and thawed between -80°C and 37°C, centrifuged at 8000g for 15 minutes, and the supernatant was transferred to a clean round-bottom centrifuge tube. The remaining steps are as follows:
[0186] a) Add 10% liquid volume of chloroform and shake horizontally at 37°C on a shaker at 200 rpm for 1 hour;
[0187] b) Add NaCl to a final concentration of 1 mol / L, dissolve and mix, and centrifuge at 12000g at 4°C for 15 minutes;
[0188] c) Transfer the supernatant to a clean round-bottom centrifuge tube, add 10 g PEG8000 per 100 ml of liquid, shake vigorously to dissolve and mix, and place on ice for 1 hour;
[0189] d) Centrifuge at 11000g for 15 minutes at 4°C, discard the supernatant, dissolve the precipitate by pipetting with pre-cooled PBS (2×) solution, and dispense the liquid into 1.5 ml EP tubes;
[0190] e) Add 1ug / ml of DNaseI and RNaseA and let stand at room temperature for 1 hour;
[0191] f) Add an equal volume of chloroform, shake and mix, then centrifuge at 12000g at 4°C for 5 minutes. Transfer the supernatant to a clean EP tube to obtain the purified virus solution.
[0192] G. Determination of virus titer
[0193] a) Take 40ul of virus solution into a clean EP tube, add 5ul of proteinase K (20mg / ml), mix well and place in a 55℃ water bath for 1 hour;
[0194] b) Add 150ul ultrapure water and 200ul phenol:chloroform:isoamyl alcohol (25:24:1), shake and mix, then centrifuge at 12000g at 4°C for 10 minutes;
[0195] c) Take the supernatant into a clean EP tube, add an equal volume of chloroform, shake and mix, and centrifuge at 12000g at 4℃ for 5 minutes. The supernatant is the viral nucleic acid;
[0196] d) Real-time quantitative PCR (CMV forward and reverse primers) is used to detect the fragment content of viral nucleic acid and calculate the virus titer. The primer sequences are shown in SEQ ID NO.3 and SEQ ID NO.4.
[0197] 3. Real-time PCR detection of lncRNA DCRT expression using Thermofisher SYBR Green:
[0198] Reverse transcription:
[0199] Reverse transcription primer (RT Primer Mix) configuration:
[0200] Oligo RT Primer 1μl
[0201] Random RT Primer 1μl
[0202] RNase free H2O 78μl
[0203] Reverse transcription reaction system:
[0204] RNA template 2μg
[0205] RT Primer Mix 4μl
[0206] RNase free H2O up to 19μl
[0207] After the above system is mixed, centrifuge it instantly, incubate it at 70℃ for 10min, incubate it on ice for 2min, and then add the following reagents:
[0208] 2×TS reaction buffer 25μl
[0209] TS enzyme 2.5 μl
[0210] RNase free H2O 3.5μl
[0211] Reverse transcription reaction procedure:
[0212] 42℃ for 60min, 70℃ for 10min; after stopping, keep at 4℃ for use, and store the product at -20℃.
[0213] Real-time PCR:
[0214] Reaction system: 2×SYBR Green Mix 9μl
[0215] RT product 2μl
[0216] lncRNA DCRT Forward Primer 2μl
[0217] lncRNA DCRT Reverse Primer 2μl
[0218] RNase-free H2O 5μl
[0219] Reaction procedure:
[0220] 95℃ 30sec--(95℃ 10sec--60℃ 20sec--70℃ 1sec)×40cycles--MeltingCurve
[0221] Primer sequences:
[0222] DCRT Forward Primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′ (SEQ ID NO.3)
[0223] DCRT Reverse Primer: 5′-AAAATGTTCCGCCCTCC-3′ (SEQ ID NO. 4).
[0224] 2. Protective effect of lncRNA DCRT on cardiac function in mice with cardiac dilatation induced by thoracic aortic constriction:
[0225] After lncRNA DCRT was highly expressed in the mouse heart, the cardiac function was detected by ultrasound and cardiac catheterization. The results showed that the full length of lncRNA DCRT had the effect of improving the impaired cardiac function in the cardiac dilatation model induced by thoracic aortic constriction ( Figure 2 A and B). Figure 2 A shows that the full length of lncRNA DCRT has the effect of improving the decreased ejection fraction in the cardiac dilatation model induced by thoracic aortic constriction, as detected by mouse ultrasound. Figure 2 B shows that the full length of lncRNADCRT was found to improve the impaired cardiac function in the cardiac dilatation model induced by thoracic aortic constriction using cardiac catheterization.
[0226] 3. Protective effect of lncRNA DCRT on pathological increase of cardiomyocytes in mice with cardiac dilatation induced by thoracic aortic constriction:
[0227] After lncRNA DCRT was highly expressed in the mouse heart, the area of mouse cardiomyocytes was detected. The results showed that the full length of lncRNA DCRT had the effect of improving the pathological increase of cardiomyocyte area induced by thoracic aortic constriction. Figure 2 C).
Claims
1. Use of the lncRNA DCRT whose sequence is shown in SEQ ID NO.1 in the preparation of a drug for treating dilated cardiomyopathy.
2. Use of the lncRNA DCRT with a sequence as shown in SEQ ID NO.1 according to claim 1 in the preparation of a drug for treating dilated cardiomyopathy, characterized in that: The reverse complementary sequence of the lncRNA DCRT is shown in SEQ ID NO.
2.
3. A drug for treating cardiovascular disease, characterized in that: The pharmacologically active ingredient uses lncRNA DCRT as a drug target, the sequence of which is shown in SEQ ID NO.1; the pharmacologically active ingredient includes: a substance that regulates the expression of lncRNA DCRT; the substance that regulates the expression of lncRNA DCRT is selected from one or two of a recombinant expression vector that overexpresses lncRNA DCRT and a transformant that overexpresses lncRNA DCRT.
4. A drug for treating cardiovascular diseases according to claim 3, characterized in that: The recombinant expression vector for overexpressing lncRNA DCRT refers to an expression vector to which the amplification product of the primer for overexpressing lncRNA DCRT is connected; Primers for overexpression of lncRNA DCRT included: forward primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′, reverse primer: 5′-AAAATGTTCCGCCCCTCC-3′; And / or, the expression vector is selected from: pAAV vector; and / or, the transformant overexpressing lncRNA DCRT is a host transformed with the recombinant expression vector; and / or, the host is selected from a recombinant adeno-associated virus or a cell; And / or, the drug further comprises: pharmaceutical excipients; And / or, the cardiovascular disease is dilated cardiomyopathy.
5. A method for preparing a drug for treating cardiovascular disease, characterized in that: The substance overexpressing lncRNA DCRT is used as the pharmacologically active ingredient of the drug; the sequence of lncRNA DCRT is such as SEQ ID NO.1; the substance overexpressing lncRNA DCRT is selected from one or two of a recombinant expression vector overexpressing lncRNA DCRT and a transformant overexpressing lncRNA DCRT; the substance overexpressing lncRNA DCRT and a pharmaceutical excipient are mixed to prepare the drug.
6. The method for preparing a drug for treating cardiovascular diseases according to claim 5, characterized in that: The recombinant expression vector for overexpressing lncRNA DCRT refers to an expression vector to which the amplification product of the primer for overexpressing lncRNA DCRT is connected; Primers for overexpression of lncRNA DCRT included: forward primer: 5′-AGATCCTCTGCTGATGTCACTTG-3′, reverse primer: 5′-AAAATGTTCCGCCCCTCC-3′; And / or, the expression vector is selected from: pAAV vector; and / or, the transformant overexpressing lncRNA DCRT is a host transformed with the recombinant expression vector; and / or, the host is selected from a recombinant adeno-associated virus or a cell; And / or, the drug further comprises: pharmaceutical excipients; And / or, the cardiovascular disease is dilated cardiomyopathy.
Citation Information
Patent Citations
Application of LncRNA (long non-coding RNA) and medicine using same
CN108096269A
Medicine for treating dilated cardiomyopathy as well as screening method and application
CN112691193A
Long non-coding rnas (lncrnas) for the diagnosis and therapeutics of brain disorders, in particular cognitive disorders
CN113286895A
Novel incrna controlling cardiac fibrosis
WO2022248574A1
